Literature DB >> 18457914

PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Corinne M Linardic1.   

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. The predominant histologic variants of this disease are termed embryonal (eRMS) and alveolar (aRMS), based on their appearance under light microscopy. Of the two, aRMS is associated with an more aggressive disease pattern and a higher mortality, mandating a better understanding of this cancer at the molecular level. The PAX3-FOXO1 fusion gene, resulting from the stable reciprocal translocation of chromosomes 2 and 13, is a signature genetic change found only in aRMS, and thought to be responsible at least in part for its malignant phenotype. This review will discuss the clinical significance of the PAX3-FOXO1 fusion gene, the pertinent historical and current models used to study its oncogenic contributions, the transcriptional targets that are thought to mediate these contributions, and the cellular mechanisms impacted by PAX3-FOXO1 that ultimately lead to aRMS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457914      PMCID: PMC2575376          DOI: 10.1016/j.canlet.2008.03.035

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  59 in total

1.  Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt.

Authors:  L del Peso; V M González; R Hernández; F G Barr; G Núñez
Journal:  Oncogene       Date:  1999-12-02       Impact factor: 9.867

Review 2.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

3.  PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

Authors:  Wendy Roeb; Antonia Boyer; Webster K Cavenee; Karen C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

4.  Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR.

Authors:  C M Margue; M Bernasconi; F G Barr; B W Schäfer
Journal:  Oncogene       Date:  2000-06-08       Impact factor: 9.867

5.  Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene.

Authors:  K Ayyanathan; W J Fredericks; C Berking; M Herlyn; C Balakrishnan; E Gunther; F J Rauscher
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Authors:  J Khan; M L Bittner; L H Saal; U Teichmann; D O Azorsa; G C Gooden; W J Pavan; J M Trent; P S Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

7.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.

Authors:  J Khan; J S Wei; M Ringnér; L H Saal; M Ladanyi; F Westermann; F Berthold; M Schwab; C R Antonescu; C Peterson; P S Meltzer
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

8.  An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.

Authors:  W J Fredericks; K Ayyanathan; M Herlyn; J R Friedman; F J Rauscher
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

9.  Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.

Authors:  M J Anderson; G D Shelton; W K Cavenee; K C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

10.  Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.

Authors:  Ken Kikuchi; Kunihiko Tsuchiya; Osamu Otabe; Takahiro Gotoh; Shinichi Tamura; Yoshiki Katsumi; Shigeki Yagyu; Satoko Tsubai-Shimizu; Mitsuru Miyachi; Tomoko Iehara; Hajime Hosoi
Journal:  Biochem Biophys Res Commun       Date:  2007-11-20       Impact factor: 3.575

View more
  56 in total

1.  AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.

Authors:  Mathivanan Jothi; Kochi Nishijo; Charles Keller; Asoke K Mal
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

2.  Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.

Authors:  Min-Hyung Lee; Mathivanan Jothi; Andrei V Gudkov; Asoke K Mal
Journal:  Cancer Res       Date:  2011-04-14       Impact factor: 12.701

Review 3.  The cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenes.

Authors:  J G Sinkovics
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

Review 4.  Trans-spliced long non-coding RNA: an emerging regulator of pluripotency.

Authors:  Chun-Ying Yu; Ching-Yu Chuang; Hung-Chih Kuo
Journal:  Cell Mol Life Sci       Date:  2018-06-30       Impact factor: 9.261

5.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Authors:  Berkley E Gryder; Marielle E Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S Wei; Frederic G Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F Shern; Keji Zhao; Craig J Thomas; Javed Khan
Journal:  Cancer Discov       Date:  2017-04-26       Impact factor: 39.397

Review 6.  Rhabdomyosarcoma in adults: new perspectives on therapy.

Authors:  Catalina Ruiz-Mesa; John M Goldberg; Alvaro J Coronado Munoz; Sarah N Dumont; Jonathan C Trent
Journal:  Curr Treat Options Oncol       Date:  2015-06

7.  Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma.

Authors:  Alexandra Lacey; Erik Hedrick; Yating Cheng; Kumaravel Mohankumar; Melanie Warren; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2018-09-06       Impact factor: 6.261

8.  Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.

Authors:  Fu-Yue Zeng; Hanqing Dong; Jimmy Cui; Lingling Liu; Taosheng Chen
Journal:  Biochem Biophys Res Commun       Date:  2009-12-06       Impact factor: 3.575

9.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

10.  PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.

Authors:  Fu-Yue Zeng; Jimmy Cui; Lingling Liu; Taosheng Chen
Journal:  Cancer Lett       Date:  2009-05-12       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.